[CAS NO. 76144-81-5] Meldonium
PRODUCTS SPECIFICATIONS [76144-81-5]
DESCRIPTION [76144-81-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 146.19 |
| Molecular Formula | C6H14N2O2 |
| SMILES | C[N+](C)(C)NCCC([O-])=O |
2 Publications Citing Use of MCE
Summary
Mildronate (Meldonium) functions as a cardioprotective drug by cpmpetetively inhibiting BBOX1 and OCTN2 . Mildronate (Meldonium) exhibits IC 50 values of 34-62 μM for human recombinant BBOX and an EC 50 of 21 μM for human OCTN2. Mildronate (Meldonium) treatment-induced redirection of long-chain FA metabolism from mitochondria to peroxisomes [1] .
IC50 & Target
IC50: 34-62 μM (human recombinant BBOX).
EC50: 21 μM (human OCTN2).
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01800357 | Xijing Hospital |
Acute Ischemic Stroke
|
January 2013 | Phase 2 |
| NCT01831011 | Xijing Hospital |
Acute Ischemic Stroke
|
July 2008 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 50 mg/mL ( 342.02 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 6.8404 mL | 34.2021 mL | 68.4041 mL |
| 5 mM | 1.3681 mL | 6.8404 mL | 13.6808 mL |
| 10 mM | 0.6840 mL | 3.4202 mL | 6.8404 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (684.04 mM); Clear solution; Need ultrasonic
References
- [1] Dambrova M, et al. Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacol Res. 2016 Nov;113(Pt B):771-780.
- [2] Schobersberger W, et al. Story behind meldonium-from pharmacology to performance enhancement: a narrative review. Br J Sports Med. 2017 Jan;51(1):22-25.
Synonyms